Childhood cancer C00-D48
Conditions
Interventions
Group 1: Intervention group 1 (IG1, n=15): Children and adolescents (5-21 years) with oncological diseases during acute medical care. They participate in a child-specific and playful sensorimotor trai
Sponsors
Deutsche Sporthochschule Köln, Institut für Kreislaufforschung und Sportmedizin, Abteilung Molekulare und Zelluläre Sportmedizin
Eligibility
Sex/Gender
All
Age
5 Years to 21 Years
Inclusion criteria
Inclusion criteria: IG1 and IG2: • age: = 6 and = 21 years • pediatric oncological disease • medical consent from the treating oncologist • written informed consent from at least one legal guardian (participants <18 years) • written informed consent from the participant IG1: • acute medical treatment including chemotherapy that requires regular inpatient stays IG2: • max. 24 months since cessation of acute medical treatment including chemotherapy
Exclusion criteria
Exclusion criteria: IG1 and IG2: • physical or severe mental impairments that make participation in the training intervention or the functional motor tests impossible from the oncologist's point of view (e.g. amputations or severe functional impairments of the lower extremities) • special circumstances (on medical recommendation) • diagnosis of a CNS-tumor (due to the accompanying balance impairments) • lack of german language skills that make comprehension of the informed consents resp. the intervention and functional motor tests impossible Contraindications (leading to interruption of the training): IG1 and IG2: - Thrombocytopenia (acute platelet count below 10,000mm³ or 20,000mm³ with bleeding signs) - Acute thrombosis - Nausea/emesis or dizziness - Fever (=38.0°C) - During severe infections - Up to 7 days after minor surgical procedures - At least 2 weeks after major surgical procedures - injuries of muscles, tendons, ligaments, joints or bones that make participation temporarily impossible
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome is the effect of the sensorimotor intervention on balance. To examine balance, the one-leg stand (qualitative and quantitative evaluation) and a pressure distribution platform (emed®, Novel gmbh, Munich) will be used at baseline (t1) and after the six-week intervention (t2). | — |
Secondary
| Measure | Time frame |
|---|---|
| As a secondary outcomes, the effects of the sensorimotor intervention on associated functional performance parameters will be investigated: - Functional walking capacity (6-minute walk test (6MWT)). - Functional lower extremity strength (sit-to-stand test, 5 repetitions) - ankle dorsiflexion range of motion (goniometer) - Chemotherapy-induced polyneuropathy (CIPN) (mod. Ped-mTNS score) After the intervention (t1), the participants' satisfaction will be assessed. The self-developed questionnaire, which has been used in previous studies, includes (1) questions on satisfaction with the training program, (2) questions on subjective-perceived effectiveness of SMT on selected physical abilities, and (3) questions on feasibility of the training modality in the different settings. Participation rates, reasons for non-participation in training sessions, feasibility of the sensorimotor sessions (duration, intensity (BORG scale, 1-10), feasibility and composition of exercises, and occurrence of intervention-related adverse events) will be collected and analyzed. In addition, relevant medical data of the participants will be recorded. | — |
Countries
Germany
Contacts
Public ContactSarah Otten
Deutsche Sporthochschule Köln, Institut für Kreislaufforschung und Sportmedizin, Abteilung Molekulare und Zelluläre Sportmedizin
Outcome results
None listed